- Major drug companies including Johnson & Johnson, Merck and Bristol Myers Squibb have committed to participate in Medicare drug price negotiations with the federal government, the Biden administration said Tuesday.
- The Centers for Medicare and Medicaid Services named the first 10 prescription drugs subject to price negotiations under the Inflation Reduction Act a little over a month ago.
- They include Eliquis and Xarelto, two blood thinners; Januvia, a diabetes drug; and Enbrel, for rheumatoid arthritis. Last year, about 9 million Medicare enrollees spent $3.4 billion out of pocket on the 10 selected drugs, according to the administration.
